2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK inhibitors against WT-ALK and many ALK resistance mutations, including…
Drug Hunter > Molecules > TPX-0131
become a member to continue reading
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.
- Stay up-to-date and save more time with exclusive members-only content
- On-board new team members with educational content and case studies
- Generate ideas and discussion with easy-to-read slide decks
- Generate ideas and discussion with easy-to-read slide decks